Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia

This study is testing a combination of two targeted drugs — ibrutinib and blinatumomab — in patients with a type of blood cancer called B-cell acute lymphoblastic leukemia (B-ALL) that has come back or stopped responding to previous treatments. **You may be eligible if...** - You have been confirmed to have relapsed or refractory B-cell ALL (a cancer of immature white blood cells that has returned or is resistant to treatment) - Your cancer has measurable disease visible on bone marrow testing or imaging (CT/PET scan) - If your cancer has a gene change called Philadelphia chromosome (Ph+), you must have tried at least one second-generation targeted therapy and it must have failed - You have had a prior stem cell transplant (this is allowed) - Your organ function meets the minimum required levels **You may NOT be eligible if...** - You have active central nervous system (brain/spinal cord) involvement that is untreated - You have uncontrolled serious infections - You are pregnant or breastfeeding - You are taking certain blood-thinning or interacting medications that cannot be stopped Talk to your doctor to see if this trial is right for you.